Lilly’s Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer’s Disease PR NewswireFDA approves second Alzheimer’s drug that can slow onset of disease The GuardianApproval of Newest Alzheimer’s Drug Will Accelerate New Era of Treatment The Wall Street JournalFDA approves new Alzheimer’s treatment, donanemab from Eli Lilly CBS News